Targets › RTASE
1 program from 1 company in 14 trials: 5 Phase 3, 4 Phase 2, 3 Phase 4, 2 Phase 1; Infectious disease, Metabolic and endocrine, Oncology; next expected readout Mar 2027.
Open in Phaseline: the race on RTASE, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| GSK | Dolutegravir Human immunodeficiency virus type 1 integrase inhibitor | INSTI, RTASE, INTEGRASE, RT | Phase 3 | HIV; HIV Infections; HIV-1-infection; Acute HIV Infection … | Mar 2027 |
HIV-1-infection (5) HIV Infections (3) HIV (2) Acute HIV Infection (1) Healthy Volunteer (1) HTLV-1 Infection (1) Tuberculosis (1)
mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.